651. Sulodexide pretreatment attenuates renal ischemia-reperfusion injury in rats.
- Author
-
Yin J, Chen W, Ma F, Lu Z, Wu R, Zhang G, Wang N, and Wang F
- Subjects
- Animals, Antithrombin III metabolism, Apoptosis drug effects, Cell Hypoxia, Cell Line, Cytoprotection, Disease Models, Animal, Humans, Kidney Diseases metabolism, Kidney Diseases pathology, Kidney Tubules metabolism, Kidney Tubules pathology, Male, Oxidative Stress drug effects, Rats, Sprague-Dawley, Reactive Oxygen Species metabolism, Reperfusion Injury metabolism, Reperfusion Injury pathology, Anti-Inflammatory Agents pharmacology, Antioxidants pharmacology, Glycosaminoglycans pharmacology, Kidney Diseases prevention & control, Kidney Tubules drug effects, Reperfusion Injury prevention & control
- Abstract
Sulodexide is a potent antithrombin agent, however, whether it has beneficial effects on renal ischemia-reperfusion injury (IRI) remains unknown. In the present study, we assessed the therapeutic effects of sulodexide in renal IRI and tried to investigate the potential mechanism. One dose of sulodexide was injected intravenously in Sprague-Dawley rats 30 min before bilateral kidney ischemia for 45 min. The animals were sacrificed at 3h and 24h respectively. Our results showed that sulodexide pretreatment improved renal dysfunction and alleviated tubular pathological injury at 24h after reperfusion, which was accompanied with inhibition of oxidative stress, inflammation and cell apoptosis. Moreover, we noticed that antithrombin III (ATIII) was activated at 3h after reperfusion, which preceded the alleviation of renal injury. For in vitro study, hypoxia/reoxygenation (H/R) injury model for HK2 cells was carried out and apoptosis and reactive oxygen species (ROS) levels were evaluated after sulodexide pretreatment. Consistently, sulodexide pretreatment could reduce apoptosis and ROS level in HK2 cells under H/R injury. Taken together, sulodexide pretreatment might attenuate renal IRI through inhibition of inflammation, oxidative stress and apoptosis, and activation of ATIII.
- Published
- 2017
- Full Text
- View/download PDF